Free Trial
NASDAQ:CTSO

Cytosorbents (CTSO) Stock Price, News & Analysis

Cytosorbents logo
$0.94 +0.01 (+0.59%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$0.95 +0.01 (+1.55%)
As of 08/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytosorbents Stock (NASDAQ:CTSO)

Key Stats

Today's Range
$0.91
$0.96
50-Day Range
$0.84
$1.29
52-Week Range
$0.71
$1.61
Volume
31,562 shs
Average Volume
387,748 shs
Market Capitalization
$58.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Moderate Buy

Company Overview

Cytosorbents Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CTSO MarketRank™: 

Cytosorbents scored higher than 43% of companies evaluated by MarketBeat, and ranked 735th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cytosorbents has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cytosorbents' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytosorbents is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytosorbents is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytosorbents has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cytosorbents' valuation and earnings.
  • Percentage of Shares Shorted

    2.35% of the float of Cytosorbents has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytosorbents has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Cytosorbents has recently decreased by 4.86%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cytosorbents does not currently pay a dividend.

  • Dividend Growth

    Cytosorbents does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.35% of the float of Cytosorbents has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytosorbents has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Cytosorbents has recently decreased by 4.86%, indicating that investor sentiment is improving.
  • News Sentiment

    Cytosorbents has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cytosorbents this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytosorbents insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.30% of the stock of Cytosorbents is held by insiders.

  • Percentage Held by Institutions

    Only 32.87% of the stock of Cytosorbents is held by institutions.

  • Read more about Cytosorbents' insider trading history.
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTSO Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Zacks Small Cap Forecasts Stronger Earnings for Cytosorbents
See More Headlines

CTSO Stock Analysis - Frequently Asked Questions

Cytosorbents' stock was trading at $0.91 at the beginning of 2025. Since then, CTSO stock has increased by 2.8% and is now trading at $0.9355.

Cytosorbents Corporation (NASDAQ:CTSO) issued its quarterly earnings results on Thursday, August, 7th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. The medical research company earned $9.62 million during the quarter, compared to analysts' expectations of $9.79 million. Cytosorbents had a negative trailing twelve-month return on equity of 111.97% and a negative net margin of 25.58%.
Read the conference call transcript
.

Cytosorbents' top institutional investors include Avenir Corp (8.06%) and Geode Capital Management LLC (0.96%). Insiders that own company stock include Phillip P Chan, Alan D Sobel, Michael G Bator and Kathleen P Bloch.
View institutional ownership trends
.

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU).

Company Calendar

Last Earnings
8/07/2025
Today
8/29/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CTSO
CIK
1175151
Employees
220
Year Founded
2002

Price Target and Rating

High Price Target
$10.00
Low Price Target
$1.00
Potential Upside/Downside
+487.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.72 million
Net Margins
-25.58%
Pretax Margin
-31.34%
Return on Equity
-111.97%
Return on Assets
-29.00%

Debt

Debt-to-Equity Ratio
1.24
Current Ratio
2.34
Quick Ratio
1.96

Sales & Book Value

Annual Sales
$35.60 million
Price / Sales
1.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.18 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
62,760,000
Free Float
58,180,000
Market Cap
$58.71 million
Optionable
Optionable
Beta
1.19

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CTSO) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners